FindTrial
Sign In

LY3214996

DRUG8 trials

Sponsors

Eli Lilly and Company, Dana-Farber Cancer Institute, Kimberly Perez, MD, Nader Sanai, Anita Turk

Conditions

Acute Myeloid LeukemiaAdvanced CancerBRAF V600ECancerCancer MetastaticChronic Lymphocytic LeukemiaColorectal CancerERK Mutation

Early Phase 1

LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients
CompletedNCT04391595
Nader SanaiGBM, Glioblastoma, Glioma
Start: 2020-07-11End: 2025-09-03Updated: 2026-03-06

Phase 1

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
CompletedNCT02857270
Eli Lilly and CompanyAdvanced Cancer, Colorectal Cancer, Metastatic Melanoma +1
Start: 2016-09-29End: 2022-10-24Updated: 2022-11-22
A Study of LY3214996 in Healthy Participants
CompletedNCT04033341
Eli Lilly and CompanyHealthy
Start: 2019-08-01End: 2019-09-09Updated: 2019-10-29
ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies
WithdrawnNCT04043845
Dana-Farber Cancer InstituteChronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma +1
Start: 2020-02-03End: 2020-02-03Updated: 2020-02-05
LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy
CompletedNCT04081259
Dana-Farber Cancer InstituteAcute Myeloid Leukemia
Start: 2020-07-15End: 2023-08-26Updated: 2025-05-08
Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers
TerminatedNCT04916236
The Netherlands Cancer InstituteColorectal Cancer, KRAS Mutation-Related Tumors, Non-small Cell Lung Cancer +1
Start: 2022-03-31End: 2024-07-30Updated: 2025-01-24

Phase 2

LY3214996 +/- HCQ in Pancreatic Cancer
CompletedNCT04386057
Kimberly Perez, MDAdvanced Cancer, Pancreatic Cancer
Start: 2020-05-27End: 2024-02-05Updated: 2025-02-12
A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.
TerminatedNCT04534283
Anita TurkBRAF V600E, Cancer, Cancer Metastatic +4
Start: 2020-10-05End: 2023-08-07Updated: 2024-08-07

Related Papers

CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer.
2026-01-22
Temporal multiomic profiling reveals intrinsic resistance mechanisms to ERK inhibition in relapsed Acute Myeloid Leukemia
Blood2025-11-03
CTNI-58. A PHASE 0/2 TRIAL OF ABEMACICLIB PLUS LY3214996 IN RECURRENT GLIOBLASTOMA
Neuro-Oncology2024-11-01
Abstract C036: Vertical inhibition of the autophagy pathway enhances sensitization to RAS MAPK pathway inhibition in pancreatic ductal adenocarcinoma
Cancer Research2024-09-15
Abstract IA-06: Elucidation of metabolic resistance mechanisms to RAS inhibition
Cancer Research2024-09-15
Abstract C026: Concurrent inhibition of the RAS ERK-MAPK pathway and PIKfyve as a therapeutic strategy for pancreatic cancer
Cancer Research2024-09-15
Abstract C047: Improving the efficacy of dual ERK-MAPK and autophagy inhibition as a therapeutic strategy for pancreatic ductal adenocarcinoma
Cancer Research2024-01-16
Clinical protocol: Feasibility of evaluating abemaciclib neuropharmacokinetics of diffuse midline glioma using intratumoral microdialysis
PLoS ONE2023-09-088 citations
A phase 2 basket trial of an ERK1/2 inhibitor (LY3214996) in combination with abemaciclib for patients whose tumors harbor pathogenic alterations in <i>BRAF</i>, <i>RAF1</i>, <i>MAP2K1/2</i> <i>ERK1/2</i>, and <i>NF1</i>.
Journal of Clinical Oncology2023-06-014 citations
Abstract IA26: Exploiting altered metabolism as a therapeutic strategy for RAS-driven cancers
Molecular Cancer Research2023-05-01
Abstract 4851: Improving the efficacy of dual ERK-MAPK and autophagy inhibition as a therapeutic strategy for pancreatic ductal adenocarcinoma
Cancer Research2023-04-04
Abstract B007: Enhancing autophagy inhibition as a therapeutic strategy for pancreatic cancer
Cancer Research2022-11-15
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer
Cell Reports Medicine2022-11-0133 citations
CTNI-48. A PHASE 0 ‘TRIGGER’ TRIAL OF CDK4/6 PLUS ERK1/2 INHIBITORS IN RECURRENT GLIOBLASTOMA
Neuro-Oncology2021-11-021 citations
DDRE-08. A BIOANALYTICAL LC-MS/MS ASSAY TO QUANTIFY TOTAL AND UNBOUND LY3214996, ABEMACICLIB AND ITS ACTIVE METABOLITES IN HUMAN PLASMA, CEREBROSPINAL FLUID AND HUMAN GLIOBLASTOMA
Neuro-Oncology2021-11-02
A Phase 0 ‘trigger’ trial of CDK4/6 plus ERK1/2 inhibitors in recurrent glioblastoma.
Journal of Clinical Oncology2021-05-205 citations
Selected Articles from This Issue
Molecular Cancer Therapeutics2021-04-01
ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine
Molecular Cancer Therapeutics2019-11-19101 citations
Abstract LB-083: Combination of an ERK1/2 inhibitor (LY3214996) with pan-RAF inhibitor enhances anti-tumor activity in <i>KRAS</i> mutant colorectal cancer (CRC) and non-small cell lung cancer (NSCLC)
Cancer Research2019-07-01
Abstract 1307: Inhibition of ERK by LY3214996 augments nab-paclitaxel and gemcitabine combination chemotherapy efficacy in preclinical models of pancreatic cancer
Cancer Research2019-07-01

5 more papers not shown